Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Kidney Failure
Study results from M. Willicombe and colleagues update understanding of kidney failure
May 18th, 2008
"Nephrogenic systemic fibrosis (NSF) was recently linked to gadolinium-based contrast (GBC) exposure in patients with renal failure. As result, the U.S.," scientists in London, the United Kingdom report. "Food and Drug Administration (FDA), the UK Commission on Human Medicines (CHM) and the European Pharmacovigilance Working Party Committee for Medicinal Products for Human Use (CHMP) recommended that GBC should be avoided in patients with advanced renal failure (GFR < 30 ml/minute/1.73 m(2)). Ones initial reaction is to advise avoidance of GBC exposure in patients with any level of kidney disease to prevent this awful complication. However, this approach is not based...
Source: Medical Letter on the CDC & FDA (2008-05-18)
|
